Abstract:Helicobacter pylori (HP) is a major causative agent of chronic gastritis and peptic ulcer. HP is also engaged in the development of gastric cancer and gastric mucosa-associated lymphoid tissue lymphoma. It is an important pathogenic factor in various other systemic diseases, such as vitamin B12 deficiency, iron deficiency, and idiopathic thrombocytopenia. The current consensus is that unless there is a special reason, eradication therapy should be implemented whenever HP infection is found, and it is ideally successful the first time. International guidelines recommend that under certain conditions, treatment should be personalized based on drug susceptibility testing. However, drug susceptibility testing is often not available because it is expensive, time-consuming, and difficult to obtain living tissue. Each region has separately formulated guidelines or consensuses on empirical therapy. Owing to an increasing drug resistance rate in various places, the eradication rate of proton pump inhibitor (PPI) triple therapy and sequential therapy has been affected. These regimens are rarely used; the PPI triple especially has been abandoned in most areas. Currently, radical treatment regimens for HP involve bismuth-containing quadruple therapy and concomitant therapy. However, quadruple therapy has its own limitations, such as complex drug administration. To improve the effectiveness, safety, and compliance, many clinical studies have proposed useful modified regimens, which mainly include the modified bismuth-containing quadruple regimen, high-dose dual therapy, and vonoprazan-containing regimens. Studies have shown that these emerging regimens have acceptable eradication rates and safety, and are expected to become first-line treatments in empirical therapy. However, the problem of decline in the eradication rate caused by drug resistance has not been fundamentally solved. This review not only summarizes the effectiveness of mainstream regimens in the first-line treatment of HP infection with the currently increasing antibiotic resistance rates, but also summarizes the effectiveness and safety of various emerging treatment regimens.

The Actuality and Expectation on Helicobacter Pylori Infection Treatment

Efficacy of quadruple therapy with clarithromycin based on faecal molecular antimicrobial susceptibility tests as first-line treatment for <i>Helicobacter pylori</i> infection: a protocol of a single-centre, single-blind, randomised clinical trial in China

Current Status of Helicobacter Pylori Eradication and Risk Factors for Eradication Failure

Short-term Outcomes and Intermediate-Term Follow-Up of Helicobacter Pylori Infection Treatment for Naïve Patients: a Retrospective Observational Study.

Progress of diagnosis and treatment schemes of Helicobacter pylori infection

Regimens and Influencing Factors of Helicobacter pylori Eradication

Recent progress in Helicobacter pylori treatment

Eradication of Helicobacter pylori: recent advances in treatment

Treatment of Helicobacter pylori infection: Past, present and future

Helicobacter pylori treatment: antibiotics or probiotics

Treatment strategies and pharmacist‐led medication management for Helicobacter pylori infection

Anti-Helicobacter pylori with traditional Chinese medicine:the innovative perspectives

The Ideal Helicobacter pylori Treatment for the Present and the Future

Multiple Bismuth Quadruple Therapy Containing Tetracyclines Combined with Other Antibiotics and Helicobacter pylori Eradication Therapy

Strategy for the Treatment of Helicobacter pylori Infection

Treatment of Helicobacter pylori infection: Current and future insights

The status and progress of first-line treatment against Helicobacter pylori infection: a review

A Multicentre Study on Eradication of Helicobacter Pylori Using Four 1-Week Triple Therapies in China.

Frailty and adherence to adjuvant hormonal therapy in older women with breast cancer: CALGB protocol 369901.

A Clinical Study of Proton Pump Inhibitor-containing Quadruple Regimen as First-line Therapy for Helicobacter pylori Eradication

Novel therapeutic regimens against Helicobacter pylori: an updated systematic review